On March 9, the 2026 Forbes China list of Top 100 Outstanding Businesswomen was officially released, and the Chairwoman of the Board of Sino Biopharmaceutical Limited (1177.HK) was once again included for her profound influence in the field of pharmaceutical innovation. This is the 12th time Forbes China has released its Top 100 Outstanding Businesswomen list. Since undertaking Chairwoman of the Board in 2015, Ms. Theresa Tse has been featured on the list eight times, continuously leading Sino Biopharmaceutical Limited to achieve breakthrough advancements in innovative drug R&D and international development, contributing to the Healthy China initiative. 

Forbes China's selects its "China's Top 100 Outstanding Businesswomen" list by studying female executives of domestic listed companies, female leaders of multinational corporations in China, and female founders of unicorn companies. After analyzing data on the business performance, capital market performance, market size, industry influence, and innovation of the businesses led by the candidates, the final 100 individuals are selected from thousands of candidates. 

As the leader of Sino Biopharmaceutical Limited, Ms. Theresa Tse has consistently driven its transformation towards a comprehensive innovation strategy, promoting business upgrades by continuously increasing R&D investment, building an international R&D platform, and executing a series of precise investments and acquisitions. She has led several M&A deals, including the acquisitions of HOB Biotech, LaNova Medicines, and Hygieia Pharmaceuticals, significantly enhancing the global competitiveness of the the company. Currently, the company's R&D pipeline ranks among the top globally, and it has established deep strategic collaborations with multinational pharmaceutical companies such as Boehringer Ingelheim, Shionogi, and Sanofi. Under her leadership, Sino Biopharmaceutical Limited has been listed among the "Top 50 Global Pharmaceutical Companies" for seven consecutive years, and its core enterprises, CTTQ Pharma and Beijing Tide Pharmaceutical, have also repeatedly been ranked in the "Top 100 Chinese Pharmaceutical Industries". 

While adhering to innovative R&D, Ms. Theresa Tse has led Sino Biopharmaceutical Limited and its member companies to actively undertake social responsibilities, participate in various public welfare and charitable activities, and promote the establishment of an Environmental, Social, and Governance (ESG) system centered on "CARE (Cure, Accessibility, Relationship, Environment)". In 2025, the company took the lead in releasing its "Carbon Neutrality Goals and Pathway Plan". It has ranked in the top 6% of global pharmaceutical companies in the S&P Global Corporate Sustainability Assessment (CSA) for two consecutive years and was the only pharmaceutical company selected for the main list of Forbes China's "2024-2025 Sustainable Development Industrial Enterprises". 

Adhering to the philosophy of "Healthy Technology, Warming More Lives", the company will continue to focus on the four core therapeutic areas of neoplasm, liver disease, respiratory, and surgery/analgesia, and is dedicated to bringing more and better medication options to patients worldwide. 
Declaration: The copyright of this article is owned by the original author or our company. Unauthorized use by means of reprinting, copying, filming, adapting, or compiling is prohibited. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited. 

Source: Forbes China Official WeChat Account